Protagonist Therapeutics (PTGX) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for Protagonist Therapeutics (PTGX) over the last 5 years, with Sep 2025 value amounting to -$0.62.
- Protagonist Therapeutics' EPS (Weighted Average and Diluted) fell 14.81% to -$0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.65, marking a year-over-year decrease of 76.28%. This contributed to the annual value of $4.23 for FY2024, which is 404.32% up from last year.
- Per Protagonist Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.62 for Q3 2025, which was down 12.73% from -$0.55 recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $3.26 in Q1 2024 and a low of -$0.84 during Q2 2022.
- Its 3-year average for EPS (Weighted Average and Diluted) is $0.13, with a median of -$0.54 in 2024.
- Per our database at Business Quant, Protagonist Therapeutics' EPS (Weighted Average and Diluted) spiked by 586.57% in 2024 and then slumped by 105.83% in 2025.
- Over the past 5 years, Protagonist Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.77 in 2021, then rose by 9.09% to -$0.70 in 2022, then soared by 174.29% to $0.52 in 2023, then soared by 286.54% to $2.01 in 2024, then dropped by 14.81% to -$0.62 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.62 in Q3 2025, compared to -$0.55 in Q2 2025 and -$0.19 in Q1 2025.